Lunai Secures First LOI for Immune Cell Therapy Achieving Tumor Regression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2025
0mins
Source: Newsfilter
- Therapeutic Breakthrough: Lunai's immune cell therapy achieved complete regression of pancreatic tumors in mouse models with no recurrence, demonstrating significant potential in treating hard-to-treat cancers.
- Clinical Trial Plans: The company is preparing to initiate a Phase I clinical trial in early 2026 to evaluate its Dendritic Cell Combination Therapy across several high-need solid tumors, aiming to improve outcomes for pancreatic cancer patients with a current five-year survival rate of only 13%.
- Manufacturing Efficiency: Lunai's DCCT is produced from healthy donor cells, significantly reducing manufacturing timelines from weeks to days, thereby lowering treatment costs and enhancing accessibility for patients.
- Accelerating Industry Recognition: As independent expert analyses confirm the strength of its data, Lunai's technology is gaining trust from an increasing number of industry partners, reflecting growing confidence in the platform's potential to deliver scalable treatments.
Analyst Views on LNAI
About LNAI
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
